10x Genomics $TXG Stock Sold by Mirador Capital Partners LP

Mirador Capital Partners LP cut its stake in shares of 10x Genomics (NASDAQ:TXG) by 46.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,979 shares of the company’s stock after selling 29,657 shares during the quarter. Mirador Capital Partners LP’s holdings in 10x Genomics were worth $3,070,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Quantinno Capital Management LP grew its position in 10x Genomics by 16.0% during the 1st quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock valued at $114,892,000 after purchasing an additional 744,558 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of 10x Genomics by 34.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock worth $43,357,000 after buying an additional 525,369 shares in the last quarter. Casdin Capital LLC bought a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $22,834,000. Clough Capital Partners L P purchased a new position in 10x Genomics in the 4th quarter worth approximately $9,955,000. Finally, Quantedge Capital Pte Ltd lifted its position in 10x Genomics by 104.2% in the 1st quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company’s stock valued at $8,843,000 after acquiring an additional 212,600 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

TXG opened at $80.65 on Friday. The stock has a market cap of $10.51 billion, a price-to-earnings ratio of -136.69 and a beta of 1.99. The firm’s fifty day moving average is $68.66 and its 200 day moving average is $43.66. 10x Genomics has a fifty-two week low of $11.16 and a fifty-two week high of $102.81.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.10. The business had revenue of $151.04 million during the quarter, compared to the consensus estimate of $146.67 million. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%. The firm’s revenue for the quarter was down 12.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.28 EPS. On average, equities research analysts predict that 10x Genomics will post -0.75 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on TXG. Leerink Partners lifted their target price on 10x Genomics from $40.00 to $90.00 and gave the stock a “market perform” rating in a report on Tuesday, September 29th. Citigroup increased their target price on 10x Genomics from $45.00 to $50.00 and gave the company a “neutral” rating in a report on Friday, August 7th. TD Cowen restated a “hold” rating on shares of 10x Genomics in a research note on Wednesday, July 15th. UBS Group assumed coverage on 10x Genomics in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $68.00 price objective on the stock. Finally, Piper Sandler lifted their price objective on 10x Genomics from $47.00 to $80.00 and gave the company a “neutral” rating in a research report on Monday, September 28th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $58.60.

Insiders Place Their Bets

In other 10x Genomics news, CEO Serge Saxonov sold 25,000 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $81.22, for a total transaction of $2,030,500.00. Following the completion of the transaction, the chief executive officer owned 1,050,249 shares of the company’s stock, valued at $85,301,223.78. This represents a 2.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Benjamin Hindson sold 13,818 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $63.02, for a total value of $870,810.36. Following the transaction, the insider owned 488,182 shares of the company’s stock, valued at approximately $30,765,229.64. The trade was a 2.75% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 179,333 shares of company stock worth $11,810,070. 8.84% of the stock is owned by corporate insiders.

10x Genomics Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at high resolution. Its platforms are used by academic and government research institutions, pharmaceutical and biotechnology companies, and other organizations studying genomics, cell biology, immunology, neuroscience, and disease mechanisms.

The company’s product portfolio includes the Chromium platform for single-cell and other multiomics analyses, the Visium platform for spatial analysis of tissue, and the Xenium platform for high-plex in situ analysis of gene expression.